ResMed Inc. (NYSE:RMD) CFO Sells $228,600.00 in Stock

Share on StockTwits

ResMed Inc. (NYSE:RMD) CFO Brett Sandercock sold 2,000 shares of the stock in a transaction that occurred on Monday, September 17th. The shares were sold at an average price of $114.30, for a total transaction of $228,600.00. Following the completion of the sale, the chief financial officer now directly owns 73,232 shares of the company’s stock, valued at approximately $8,370,417.60. The transaction was disclosed in a filing with the SEC, which is available through the SEC website.

Brett Sandercock also recently made the following trade(s):

  • On Wednesday, August 15th, Brett Sandercock sold 2,000 shares of ResMed stock. The stock was sold at an average price of $107.45, for a total transaction of $214,900.00.
  • On Monday, July 16th, Brett Sandercock sold 2,000 shares of ResMed stock. The stock was sold at an average price of $109.01, for a total transaction of $218,020.00.

ResMed stock traded up $1.41 during mid-day trading on Friday, reaching $103.25. 652,391 shares of the company’s stock were exchanged, compared to its average volume of 684,547. The firm has a market cap of $16.46 billion, a PE ratio of 29.25, a price-to-earnings-growth ratio of 2.94 and a beta of 0.87. ResMed Inc. has a twelve month low of $77.27 and a twelve month high of $116.64. The company has a quick ratio of 1.56, a current ratio of 2.08 and a debt-to-equity ratio of 0.13.

ResMed (NYSE:RMD) last released its earnings results on Thursday, August 2nd. The medical equipment provider reported $0.95 earnings per share (EPS) for the quarter, hitting the Zacks’ consensus estimate of $0.95. ResMed had a net margin of 13.49% and a return on equity of 24.74%. The company had revenue of $623.63 million for the quarter, compared to analyst estimates of $622.78 million. During the same period in the prior year, the business earned $0.77 EPS. The firm’s quarterly revenue was up 12.0% on a year-over-year basis. On average, equities research analysts anticipate that ResMed Inc. will post 3.71 earnings per share for the current fiscal year.

The company also recently disclosed a quarterly dividend, which was paid on Thursday, September 20th. Stockholders of record on Thursday, August 16th were issued a $0.37 dividend. This represents a $1.48 dividend on an annualized basis and a dividend yield of 1.43%. This is a positive change from ResMed’s previous quarterly dividend of $0.35. The ex-dividend date of this dividend was Wednesday, August 15th. ResMed’s dividend payout ratio (DPR) is presently 41.93%.

A number of research firms recently weighed in on RMD. Zacks Investment Research raised shares of ResMed from a “sell” rating to a “hold” rating in a research report on Tuesday, July 31st. Goldman Sachs Group began coverage on shares of ResMed in a research report on Sunday, July 1st. They set a “buy” rating for the company. Two analysts have rated the stock with a sell rating, six have issued a hold rating and four have assigned a buy rating to the stock. ResMed has a consensus rating of “Hold” and a consensus price target of $81.60.

Several institutional investors and hedge funds have recently made changes to their positions in the company. BlackRock Inc. raised its holdings in shares of ResMed by 0.4% in the 1st quarter. BlackRock Inc. now owns 11,187,425 shares of the medical equipment provider’s stock valued at $1,101,627,000 after purchasing an additional 43,363 shares in the last quarter. JPMorgan Chase & Co. raised its holdings in shares of ResMed by 191.2% in the 1st quarter. JPMorgan Chase & Co. now owns 971,754 shares of the medical equipment provider’s stock valued at $95,687,000 after purchasing an additional 638,038 shares in the last quarter. Morgan Stanley raised its holdings in shares of ResMed by 30.2% in the 2nd quarter. Morgan Stanley now owns 966,736 shares of the medical equipment provider’s stock valued at $100,135,000 after purchasing an additional 223,963 shares in the last quarter. Schwab Charles Investment Management Inc. grew its position in shares of ResMed by 12.1% in the 2nd quarter. Schwab Charles Investment Management Inc. now owns 813,087 shares of the medical equipment provider’s stock valued at $84,220,000 after buying an additional 87,893 shares during the last quarter. Finally, Millennium Management LLC grew its position in shares of ResMed by 2,526.7% in the 1st quarter. Millennium Management LLC now owns 769,536 shares of the medical equipment provider’s stock valued at $75,776,000 after buying an additional 740,239 shares during the last quarter. Institutional investors and hedge funds own 63.81% of the company’s stock.

ResMed Company Profile

ResMed Inc develops, manufactures, distributes, and markets medical devices and cloud-based software applications that diagnose, treat, and manage respiratory disorders comprising sleep disordered breathing, chronic obstructive pulmonary disease, neuromuscular disease, and other chronic diseases. It offers various products and solutions for a range of respiratory disorders, including technologies to be applied in medical and consumer products, ventilation devices, diagnostic products, mask systems for use in the hospital and home, headgear and other accessories, dental devices, portable oxygen concentrators, and cloud-based software informatics solutions to manage patient outcomes, as well as provides customer and business processes.

Featured Article: Balance Sheet

Insider Buying and Selling by Quarter for ResMed (NYSE:RMD)

Receive News & Ratings for ResMed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ResMed and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply